A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer Research (UK) and entered clinical trials in 1991; phase II studies began in 1992, using 3.0...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Smith, I., Jones, A., Spielmann, M., Namer, M., Green, M. D., Bonneterre, J., Wander, H. E., Hatschek, T., Wilking, N., Zalcberg, J., Spiers, J., Seymour, L.
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 1996
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074654/
https://ncbi.nlm.nih.gov/pubmed/8695369
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍